Integrated approaches to sensitizing melanoma to radiotherapy

Melanoma presents significant challenges to treatment due to its complex tumor microenvironment (TME) and the development of various resistance mechanisms in cancer cells. Radiotherapy is one of the main treatment modalities for melanoma. It acts by generating reactive oxygen species (ROS) and inducing DNA damage in melanoma cancer cells. However, these malignant cells develop DNA damage responses (DDRs) to resist ionizing radiation (IR). In addition, tumor cells engage in constant dialogue with surrounding stromal cells, immune cells, and extracellular matrix (ECM) components. These interactions shape tumor progression, metastasis, and resistance to different antitumor agents, including radiotherapy. Key players in this cellular orchestra include stromal cells, macrophages, myeloid cells, and different subsets of T cells. In addition, a unique vascular system and subsequent hypoxia in some regions of the tumor can further stimulate resistance to radiotherapy. Emerging research highlights the role of immune checkpoints, hypoxia, growth factors, and growth factor receptors in modulating tumor responses to radiation. Recent studies have uncovered promising molecular targets such as DNA repair inhibitors, immune checkpoint inhibitors (ICIs), tyrosine kinase inhibitors (TKIs), and hypoxia modulators to sensitize melanoma to radiotherapy. This review aims to synthesize current knowledge on melanoma tumor interactions, providing a comprehensive overview of promising targets for improving radiotherapy outcomes in melanoma patients.